Navigation Links
BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review
Date:5/3/2011

NEWARK, N.J., May 3, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced that it has signed on to introduce its all new EPA-approved Ygiene® 206 hospital-grade disinfectant technology to the infection control professionals attending the 38th Annual APIC Conference (Association for Professionals in Infection Control and Epidemiology) (www.apic.org). Ygiene® is BioNeutral's latest weapon against hospital-acquired infections (HAIs), an ongoing and potential threat in the health care industry.

This year's APIC conference will be held on June 27th through June 29th, 2011 in Baltimore, MD. Recognized as the largest annual gathering of infection preventionists in the world, APIC brings together the leaders in clinical infection prevention in an interactive and educational forum. Infection preventionists are given an unprecedented opportunity to learn and engage with experts from across the global healthcare industry.

Further, BioNeutral announced that the Community Health Network of South Florida (CHI) http://www.chisouthfl.org/chi.htm will introduce Ygiene® to its Product Review Committee for evaluation and potential use among its network of facilities. CHI currently operates seven (7) state-of-the-art primary care centers and twenty-seven (27) school-based programs. Ms. Mary Ann Worts, BHSA, R.N., Director of Education and Infection Prevention and Control at CHI, stated,

"After careful review of the EPA approved data,  Ygiene  206 appears to be cutting-edge technology in the battle against microorganisms/pathogens in the healthcare industry. I have had the opportunity to compare our current universal disinfectant with Ygiene 206 and found Ygiene to be far superior.  The fact that the data reveals Ygiene has superior kill times, is a sporicidal, is non-corrosive, (crucial in the maintenance of instruments), and is a sterilant makes it  superior to our current universal disinfectant."  Ms. Worts went on to say  "As an infection prevention and control practitioner I know first-hand that HAIs  (Hospital Acquired Infections) are continuing to reek havoc in our healthcare systems. It is imperative that we put an end to this preventable healthcare tragedy.  I feel that this product compels  me to introduce it to our Product Review Committee. Upon review and approval from our Review Committee, we intend to initiate a Purchase Order and use Ygiene 206 throughout our Organizations network."

"We are extremely pleased to have the opportunity to formally introduce our Ygiene sterilant to such a wide spectrum of infection control professionals at the upcoming APIC global conference," stated Dr. Andrew Kielbania, Chief Scientist at BioNeutral Group. "To simultaneously gain the attention of a leading infection control field practitioner like Ms. Worts BHSA, R.N. of CHI clearly shows we are on the right path."

About CHI

Community Health of South Florida, Inc. a non-profit health care organization providing affordable quality primary and behavioral health care services to the residents of rapidly growing South Florida. CHI operates seven (7) state-of-the-art primary care centers and twenty-seven (27) school-based programs. All centers offer quality comprehensive primary and behavioral health care services. All physicians are board certified or board eligible. Additionally, CHI is accredited by the Joint Commission (JC). CHI offers a "one-stop-shop" model where the organization and delivery of quality services are seamless, affordable, accessible and culturally sensitive.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, NJ, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States, has previously been approved for sale in Germany and is also permitted for sale in the UK, France and Sweden. AutoNeutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of the Company's products, leadership and background, please visit www.bioneutralgroup.com.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene®-206 BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and will soon be available for sale in the United States.

Media Contact:
Matt Rizzetta
North 6th Agency
mrizzetta@north6thagency.com
718-744-7138
Investor Relations Contact:
Jeff Ramson
ProActive Capital Resources Group, LLC
jramson@proactivecrg.com
212-792-4294
FOR THE COMPANY:
Stephen J. Browand BioNeutral Group, Inc. steve@bioneutralgroup.com 973-286-2899


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
2. BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
3. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)
4. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
5. BioNeutral Group to Receive Economic Development Incentives
6. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
8. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
9. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
10. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
11. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
(Date:1/7/2016)... Various factors have contributed to the ... biologics and biosimilars. Some of these factors include ... demand for cost-effective alternatives, growing burden of chronic ... versions of their corresponding patented biologic drugs, and ... and efficacy. The global biosimilars market is estimated ...
Breaking Biology News(10 mins):